Strive CEO responds to Grayscale report: STRC dividends depend on Bitcoin price appreciation
Svmuu News: Strive CEO ColeMacro responded to a Grayscale report, stating that the report indicated Strategy's long-term ability to pay STRC dividends depends on an increase in the Bitcoin price. ColeMacro said that demand for digital credit is enormous because it offers double-digit yields, low volatility, and is easy for credit risk investors to understand and favor. He also pointed out that the report failed to discuss volatility and had shortcomings in its credit analysis. (BitcoinTreasuries.NET)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
9
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
10
Coldcard Wallet Incident Bitcoin: Estimated Losses Rise to $70 Million
Markets Today
Recommended Reading







